Kelly Stevens,
Research Scientist,
Massachusetts Institute of Technology
Kelly Stevens is a Research Scientist in the laboratory of Dr. Sangeeta Bhatia at MIT. She received a Ph.D. from the University of Washington and completed postdoctoral training at the Massachusetts Institute of Technology. Her work bridges several facets of regenerative medicine, including pluripotent stem cell biology, transplantation, tissue engineering, and micro/nanofabrication. In particular, she has made several seminal contributions in the development of complex multicellular tissues, with increasing focus on enhancing tissue function, microvascularization, and organization. Some examples include the construction of functional scaffold-free cardiac tissue from pluripotent stem cells, the subsequent ‘pre-vascularization’ of these tissues using the intrinsic capacity of microvascular cells to self-organize, and the geometric control of multicellular patterning for optimal parenchymal function and microvascular ingrowth following implantation.
Engineering Synthetic Tissues for Treatment of Chronic Liver Disease
Tuesday, 10 February 2015 at 16:30
Add to Calendar ▼2015-02-10 14:30:002015-02-10 15:30:00Europe/LondonEngineering Synthetic Tissues for Treatment of Chronic Liver DiseaseTissue Engineering and Bioprinting: Research to Commercialization in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
Cell-based therapies for organ regeneration have recently emerged as a
potential alternative to whole-organ transplantation. Unfortunately,
orthotopic cell-based therapy may not be feasible or effective in all
diseased organs. For example, in end-stage liver disease, the
inhospitable fibrotic microenvironment in cirrhotic liver is likely to
limit cellular engraftment. Our goal is to build functionally stabilized
engineered tissues that can be implanted ectopically and ultimately
used to contribute to host liver functions. To create functionally
stable engineered liver tissue, we have developed versatile microtissue
molding and bioprinting-based methods that enables rapid, scalable, and
multicompartmental cellular placement in various patterns and material
systems across tissue sizes relevant for in vitro, pre-clinical, and
clinical biologic studies. We have used these methods to identify
multicellular architectural tissue configurations that best support
parenchymal primary human or induced pluripotent stem cell (iPS)-derived
hepatocyte survival and function in vitro and in vivo. Ongoing work
seeks to extend these findings for application liver repair and
regeneration using canonical liver injury model systems.
Add to Calendar ▼2015-02-09 00:00:002015-02-10 00:00:00Europe/LondonTissue Engineering and Bioprinting: Research to CommercializationTissue Engineering and Bioprinting: Research to Commercialization in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-02-10 14:30:002015-02-10 15:30:00Europe/LondonEngineering Synthetic Tissues for Treatment of Chronic Liver DiseaseTissue Engineering and Bioprinting: Research to Commercialization in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
